Staar Surgical Company (STAA)
NASDAQ:STAA
STAA Stock Chart & Stats
$26.44
-$1.18(-4.94%)
At close: 4:00 PM EST
$26.44
-$1.18(-4.94%)
Day’s Range― - ―
52-Week Range$15.59 - $30.81
Previous CloseN/A
Volume326.32K
Average Volume (3M)1.34M
Market Cap
$1.31B
Enterprise Value$1.19B
Total Cash (Recent Filing)$187.54M
Total Debt (Recent Filing)$38.35M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
May 06, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding49,512,750
10 Day Avg. Volume1,346,835
30 Day Avg. Volume1,338,953
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)3.40
Price to Sales (P/S)4.89
P/FCF Ratio-29.21
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue4.99
Enterprise Value/Gross Profit6.60
Enterprise Value/Ebitda-31.87
Forecast
1Y Price Target
$20.75Price Target Upside-21.52% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.41
Revenue Forecast (FY)$300.47M
Bulls Say, Bears Say
Bulls Say
China Recovery And Product LaunchManagement expects China stabilization to drive sales through higher selling prices, market share gains, and the local launch of the EVO+ ICL supported by Swiss manufacturing that avoids tariff exposure.
Distributor Restocking Driving Reported SalesTermination of the proposed Alcon merger likely prompted distributor restocking that boosted reported sales and contributed to revenue beating expectations.
Profitability ImprovementManagement signaled a meaningful improvement in adjusted profitability and right-sizing of costs positions the company to support revenue growth while improving margins.
Bears Say
China Demand Sustainability RiskUnclear sell-through trends in China and signs that some strength reflects procedural pull-forward or stocking raise doubts about the durability of revenue growth.
Geopolitical And Regional Macro HeadwindsGeopolitical conflict in the Middle East and broader macro challenges across EMEA and APAC have hurt activity in key markets and could constrain revenue in affected regions.
Leadership And Governance UncertaintyLack of a permanent chief executive officer and recent boardroom changes create uncertainty about future execution and strategic direction.
Staar Surgical News
STAA FAQ
What was Staar Surgical Company’s price range in the past 12 months?
Staar Surgical Company lowest stock price was $15.59 and its highest was $30.81 in the past 12 months.
What is Staar Surgical Company’s market cap?
Staar Surgical Company’s market cap is $1.31B.
When is Staar Surgical Company’s upcoming earnings report date?
Staar Surgical Company’s upcoming earnings report date is May 06, 2026 which is in 23 days.
How were Staar Surgical Company’s earnings last quarter?
Staar Surgical Company released its earnings results on Mar 03, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of $0.18 by -$0.38.
Is Staar Surgical Company overvalued?
According to Wall Street analysts Staar Surgical Company’s price is currently Overvalued.
Does Staar Surgical Company pay dividends?
Staar Surgical Company does not currently pay dividends.
What is Staar Surgical Company’s EPS estimate?
Staar Surgical Company’s EPS estimate is 0.08.
How many shares outstanding does Staar Surgical Company have?
Staar Surgical Company has 49,512,750 shares outstanding.
What happened to Staar Surgical Company’s price movement after its last earnings report?
Staar Surgical Company reported an EPS of -$0.2 in its last earnings report, missing expectations of $0.18. Following the earnings report the stock price went up 1.586%.
Which hedge fund is a major shareholder of Staar Surgical Company?
Currently, no hedge funds are holding shares in STAA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Staar Surgical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.75 (-21.52% Downside)
$20.75 (-21.52% Downside)
Blogger Sentiment
Bullish
STAA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 58.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.8%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
69.81%
12-Months-Change
Fundamentals
Return on Equity
-23.24%
Trailing 12-Months
Asset Growth
-9.40%
Trailing 12-Months
Company Description
Staar Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed cautious optimism and a constructive tone: the company delivered solid quarter-over-quarter and year-over-year operational improvements (notably strong Q4 sales growth, significant China quarter recovery, gross margin expansion, near-breakeven adjusted EBITDA, cash strength and cost discipline) while acknowledging material challenges that impacted 2025 (China channel inventory rebalancing, distributor returns, EMEA disruption and merger-related costs). Management outlined clear actions—Swiss manufacturing, product launches (EVO+), ERP and platform investments, and maintained cost discipline—aimed at driving growth and profitability in 2026, though near-term headwinds and macro uncertainty, particularly in China and some channel risks, remain.View all STAA earnings summariesSTAA Stock 12 Month Forecast
Average Price Target
$20.75
▼(-21.52% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---